Imagine preparing for a surgery that could make fatherhood possible. You spend months taking hormone injections, hoping to boost your body’s ability to produce sperm. Then, the results show the extra hormones didn’t change your odds of success. That’s the reality for many men facing a specific type of infertility.
A new study questions a common medical practice. It looks at whether hormone therapy before a delicate sperm-retrieval surgery actually helps. The findings suggest it may not be worth the time and effort for many patients.
Infertility affects millions of couples worldwide. When the issue is on the male side, it can be especially challenging. One condition, called non-obstructive azoospermia (NOA), means the testicles don’t produce enough sperm to be found in an ejaculation.
About 1% of men have this condition. For them, a surgery called microdissection testicular sperm extraction (Micro-TESE) is often the last hope. This surgery allows doctors to find tiny pockets of sperm directly inside the testicle. But the surgery is invasive and expensive. Doctors are always looking for ways to improve the chances of success.
Many doctors prescribe hormone therapy before the surgery. The idea is to “wake up” the testicles and encourage sperm production. But this practice has been controversial. Does it really work? This study adds a crucial piece to that puzzle.
The Old Way vs. The New Way
For years, the thinking has been: if the testicles aren’t making sperm, maybe hormones can jump-start the process. Doctors often use a combination of drugs. One is a pill called clomiphene citrate. The other is an injection of human chorionic gonadotropin (hCG).
The goal is to mimic the body’s natural signals to produce testosterone and sperm. The hope is that after a few months of this therapy, the surgery will find more sperm.
But here’s the twist. This new research challenges that assumption. It suggests that for many men, this pre-surgery hormone plan doesn’t significantly change the outcome. The odds of finding sperm in the operating room were nearly the same, whether the patient had the hormones or not.
How It Works: A Simple Analogy
Think of sperm production like a factory. In men with NOA, the factory is struggling. The assembly lines are broken or idle.
The hormone therapy is like sending a memo to the factory manager. The memo says, “We need more product!” The manager (the brain) sends signals (hormones) to the factory (the testicles). The hope is that these signals will repair the assembly lines and get production going.
Micro-TESE surgery is like sending a highly skilled team into the factory to search for any finished products that might be hidden in a back corner. The study asks: Does sending the memo first make it easier for the team to find the product?
The answer, according to this research, is: not really. The team’s success rate was almost the same with or without the memo.
Researchers looked back at 152 men with NOA who had Micro-TESE surgery at one center between 2021 and 2023. About half (78 men) received hormone therapy for at least three months before surgery. The other half (74 men) went straight to surgery without any hormone treatment. The scientists then compared how often sperm was successfully retrieved in both groups.
The results were clear and surprising to some. The success rate for finding sperm was very similar in both groups.
In the group that did not receive hormones, surgeons found sperm in 50% of cases. In the group that did receive hormones, the success rate was 45%. This difference is not considered statistically significant. It means the difference could easily be due to chance.
The study did find one hormonal change. Men who took the therapy had lower levels of a hormone called FSH before surgery. But this change did not translate into a higher sperm retrieval rate.
This doesn’t mean hormone therapy is useless for everyone.
This study adds to a growing body of evidence questioning the routine use of pre-surgery hormone therapy for all NOA patients. The researchers note that while the overall success rate didn’t improve, some individual patients might still benefit. The challenge is figuring out who those patients are. Future research needs to find biomarkers—specific signs in the body—that can predict which men will respond to the hormones.
If you or your partner are dealing with NOA and considering Micro-TESE, this study is important information to discuss with your doctor. It suggests that the standard hormone therapy may not be a necessary step for everyone. You can have a more informed conversation about the potential benefits versus the time, cost, and side effects of the treatment.
This study has important limits. It was a retrospective study, meaning it looked at past data rather than assigning treatments in real-time. This can introduce bias. The sample size of 152 men is also relatively small. Finally, it was conducted at a single center, so the results may not apply to all populations or clinics.
So, what happens next? This study doesn’t end the debate on hormone therapy before Micro-TESE. Instead, it fuels the need for larger, more rigorous trials. Researchers will continue to look for better ways to predict which men will benefit from hormone stimulation. The ultimate goal is to personalize treatment, giving each patient the best possible chance of success while avoiding unnecessary steps. For now, the conversation between patient and doctor is more important than ever.
